Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
09 janv. 2025 07h00 HE
|
Climb Bio, Inc.
Transaction Expands Climb Bio’s Pipeline of B-cell Targeted Therapeutics to Address Immune-mediated Diseases New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody...
Climb Bio to be Added to the Nasdaq Biotechnology Index
19 déc. 2024 07h00 HE
|
Climb Bio, Inc.
WELLESLEY HILLS, Mass., Dec. 19, 2024 (GLOBE NEWSWIRE) -- December 19, 2024 – Climb Bio, Inc. (Nasdaq: CLYM) today announced that the company will be added to the NASDAQ Biotech Index (Nasdaq: NBI)...
Climb Bio Reports Third Quarter 2024 Financial Results and Business Highlights
12 nov. 2024 16h05 HE
|
Climb Bio, Inc.
Appointed Douglas Williams, Ph.D. as Chair of the Board of Directors FDA Clearance of Investigational New Drug Application (IND) for systemic lupus erythematosus (SLE) Expanded Management...
Climb Bio Appoints Douglas E. Williams, Ph.D., as Chair of the Board
11 nov. 2024 07h00 HE
|
Climb Bio, Inc.
WELLESLEY, Mass., Nov. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointment of Douglas E. Williams, Ph.D., as Climb Bio’s Chair of its Board of Directors. Dr....
Climb Bio to Present at Upcoming Investor Conferences
31 oct. 2024 07h00 HE
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that members of its executive team are scheduled to participate in the upcoming investor conferences...
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
15 oct. 2024 07h00 HE
|
Climb Bio, Inc.
Completes Transition to Immune-Mediated Disease Focused Company Highlights Additional Data from Phase 1b Primary Membranous Nephropathy (pMN) Study with plans to Advance to Late Phase Development...
Climb Bio Announces Abstract Selected for Presentation at the American Society of Nephrology Kidney Week 2024
11 oct. 2024 12h30 HE
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced that it will present data at the American Society of Nephrology Kidney Week 2024, which will take place...
Climb Bio to Present at William Blair’s Upcoming Conference Event on Transforming Autoimmune Diseases by Targeting CD19
04 oct. 2024 07h00 HE
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will present and host investor meetings at William Blair’s Transforming Autoimmune Diseases by...
Climb Bio to Host Virtual Investor Event on October 15, 2024
03 oct. 2024 10h00 HE
|
Climb Bio, Inc.
WELLESLEY, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), announced today it will host a virtual investor day on October 15, 2024. The event will feature members of Climb...
Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.
02 oct. 2024 09h00 HE
|
Eliem Therapeutics, Inc.
Name change to "Climb Bio" marks the Company’s transition and focus on developing treatments for immune-mediated diseases Climb Bio will begin trading on Nasdaq under the trading symbol "CLYM"...